Cargando…
Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence
Venous thromboembolic disease (VTED) is a common and clinically important complication in patients with cancer, contributing to its mortality and morbidity. Direct oral anticoagulant agents (DOACs), including direct thrombin inhibitors and direct factor Xa inhibitors, are as effective as vitamin K a...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084841/ https://www.ncbi.nlm.nih.gov/pubmed/33206333 http://dx.doi.org/10.1007/s12094-020-02506-4 |
_version_ | 1783686237422354432 |
---|---|
author | García-Escobar, I. Brozos-Vázquez, E. Gutierrez Abad, D. Martínez-Marín, V. Pachón, V. Muñoz Martín, A. J. |
author_facet | García-Escobar, I. Brozos-Vázquez, E. Gutierrez Abad, D. Martínez-Marín, V. Pachón, V. Muñoz Martín, A. J. |
author_sort | García-Escobar, I. |
collection | PubMed |
description | Venous thromboembolic disease (VTED) is a common and clinically important complication in patients with cancer, contributing to its mortality and morbidity. Direct oral anticoagulant agents (DOACs), including direct thrombin inhibitors and direct factor Xa inhibitors, are as effective as vitamin K antagonists for the treatment of VTED and are associated with less frequent and severe bleeding. They have advantages over low-molecular-weight heparin, but comparative long-term efficacy and safety data are lacking for these compounds. Recent randomized clinical trials suggest a role for DOACs in the treatment of VTED in patients with cancer. This review will discuss the existing evidence and future perspectives on the role of DOACs in the treatment of VTE based on the current evidence about their overall efficacy and safety and the limited information in patients with cancer; in addition, we will briefly review their pharmacokinetic properties with special reference to potential interactions. |
format | Online Article Text |
id | pubmed-8084841 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-80848412021-05-05 Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence García-Escobar, I. Brozos-Vázquez, E. Gutierrez Abad, D. Martínez-Marín, V. Pachón, V. Muñoz Martín, A. J. Clin Transl Oncol Review Article Venous thromboembolic disease (VTED) is a common and clinically important complication in patients with cancer, contributing to its mortality and morbidity. Direct oral anticoagulant agents (DOACs), including direct thrombin inhibitors and direct factor Xa inhibitors, are as effective as vitamin K antagonists for the treatment of VTED and are associated with less frequent and severe bleeding. They have advantages over low-molecular-weight heparin, but comparative long-term efficacy and safety data are lacking for these compounds. Recent randomized clinical trials suggest a role for DOACs in the treatment of VTED in patients with cancer. This review will discuss the existing evidence and future perspectives on the role of DOACs in the treatment of VTE based on the current evidence about their overall efficacy and safety and the limited information in patients with cancer; in addition, we will briefly review their pharmacokinetic properties with special reference to potential interactions. Springer International Publishing 2020-11-18 2021 /pmc/articles/PMC8084841/ /pubmed/33206333 http://dx.doi.org/10.1007/s12094-020-02506-4 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Article García-Escobar, I. Brozos-Vázquez, E. Gutierrez Abad, D. Martínez-Marín, V. Pachón, V. Muñoz Martín, A. J. Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence |
title | Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence |
title_full | Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence |
title_fullStr | Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence |
title_full_unstemmed | Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence |
title_short | Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence |
title_sort | direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084841/ https://www.ncbi.nlm.nih.gov/pubmed/33206333 http://dx.doi.org/10.1007/s12094-020-02506-4 |
work_keys_str_mv | AT garciaescobari directoralanticoagulantsforthetreatmentandpreventionofvenousthromboembolisminpatientswithcancercurrentevidence AT brozosvazqueze directoralanticoagulantsforthetreatmentandpreventionofvenousthromboembolisminpatientswithcancercurrentevidence AT gutierrezabadd directoralanticoagulantsforthetreatmentandpreventionofvenousthromboembolisminpatientswithcancercurrentevidence AT martinezmarinv directoralanticoagulantsforthetreatmentandpreventionofvenousthromboembolisminpatientswithcancercurrentevidence AT pachonv directoralanticoagulantsforthetreatmentandpreventionofvenousthromboembolisminpatientswithcancercurrentevidence AT munozmartinaj directoralanticoagulantsforthetreatmentandpreventionofvenousthromboembolisminpatientswithcancercurrentevidence AT directoralanticoagulantsforthetreatmentandpreventionofvenousthromboembolisminpatientswithcancercurrentevidence |